Oncology
Excerpt from the Press Release: Now has orphan drug designation for SCLC and AML MADRID, Spain and CAMBRIDGE, Mass., June 08, 2022 (GLOBE NEWSWIRE) — Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the U.S. Food and…
Read MoreCuris scientists discover novel IRAK4 nuclear localization and describe potential use as a biomarker IRAK4 along with NF-kB p50/p65 localization to the nucleus is associated with improved response to emavusertib Promising clinical and preclinical analysis showcases the potential of emavusertib in treating pCNSL Excerpt from the Press Release: LEXINGTON, Mass., June 10, 2022 /PRNewswire/ — Curis, Inc.…
Read MorePreclinical data demonstrate VIP152 as the most selective CDK9 inhibitor compared with other CDK9 inhibitors, with the most robust MYC mRNA downregulation Clinical data show improved selectivity, target modulation, early signs of clinical efficacy, and cardiac safety in lymphoma patients treated with VIP152 Excerpt from the Press Release: PALO ALTO, Calif., June 10, 2022 (GLOBE…
Read More– Long-term data at the European Hematology Association (EHA) 2022 Congress expands understanding of the impact of Genentech medicines in early-stage blood cancers with the goal of providing patients with robust and durable outcomes from their first treatment– – Updated data from Phase III CLL14 study of Venclexta (venetoclax) plus Gazyva (obinutuzumab) showed more than…
Read MoreExcerpt from the Press Release: SAN DIEGO, June 2, 2022 /PRNewswire/ — Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the acceptance of seven key oncology research abstracts authored in collaboration with Illumina at the American Society of Clinical Oncology (ASCO) annual meeting taking place June 3 – June 7…
Read MoreConfirmed objective response rate was 50% for patients treated with TTFields together with standard-of-care chemotherapy Duration of response was 10.3 months One-year survival was 72% Excerpt from the Press Release: ST. HELIER, Jersey & SHANGHAI, China & SAN FRANCISCO & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a global oncology company working to extend survival in some…
Read MoreDurable responses achieved in highly refractory patients as monotherapy (one patient with relapsed squamous cell lung cancer) and in combination with pembrolizumab (several subjects with relapsed squamous cell carcinoma of the anal canal and head and neck squamous cell carcinoma) Dose escalation portion of the study has completed and recommended dose declared, as monotherapy and…
Read MoreLEADER Trial Will Use Results from Foundation Medicine’s Comprehensive Genomic Profiling Tests to Screen for Actionable Driver Mutations to Inform Trial Enrollment and Targeted Therapy Options for Patients New “Trial in Progress” Abstract at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Details LEADER’s Primary Objective to Determine the Proportion of Patients Possessing Actionable…
Read MoreConfirmed objective response rate was 50% for patients treated with TTFields together with standard-of-care chemotherapy Duration of response was 10.3 months One-year survival was 72% Excerpt from the Press Release: Excerpt from the Press Release: ST. HELIER, Jersey & SHANGHAI, China & SAN FRANCISCO & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a global oncology company working…
Read MoreExcerpt from the Press Release: SANTA CLARA, Calif., May 24, 2022 /PRNewswire/ — Invenio Imaging, the leader in intraoperative fresh tissue imaging, announced today the CE Mark for the NIO Glioma Reveal image analysis module. NIO Glioma Reveal is based on deep learning and allows neurosurgeons to identify areas of cancer infiltration in patients undergoing primary…
Read More